MAM
FPRX

Martingale Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Martingale Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-9,106
Closed -$330K – 1016
2017
Q1 		$330K Sell
9,106
-2,400
-21% -$106K ﹤0.01% 868
2016
Q4 		$577K Buy
11,506
+353
+3% +$18.5K 0.01% 807
2016
Q3 		$586K Buy
+11,153
New +$533K 0.01% 788

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Martingale Asset Management's FPRX Position: Q2 2017 in Review

Martingale Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 9,106 shares — an estimated $330K sold.

Martingale Asset Management first reported a position in FPRX in Q3 2016 and held it in 3 quarters. The position peaked at $586K in Q3 2016. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

  • Martingale Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Martingale Asset Management sold 9,106 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $330K.
  • Martingale Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 3 quarters.
  • Martingale Asset Management's Five Prime Therapeutics, Inc. position peaked at $586K in Q3 2016.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Martingale Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.